期刊文献+

华法令预防非瓣膜性房颤患者并发脑梗塞的临床分析 被引量:9

下载PDF
导出
摘要 目的:分析华法令在防治非瓣膜性房颤患者并发脑梗塞中的作用。方法:选择近期于笔者所在医院心血管内科住院的非瓣膜房颤患者102例。随机分成两组,观察组66例采用华法令治疗,对照组36例采用阿司匹林治疗。比较两组临床预防脑梗塞的临床效果。结果:观察组发生脑梗塞发生率为3.0%,显著低于对照组的11.1%;观察组牙龈出血发生率3.0%,上腹部不适9.1%,均显著低于对照组8.3%、13.9%,差异具有统计学意义(P<0.05)。观察组皮下少量紫斑发生率为3.0%,与对照组的2.8%比较,差异无统计学意义(P>0.05)。结论:华法林可明显降低非瓣膜性房颤病患者发生脑梗塞几率。
作者 张乃奇
机构地区 济宁交通医院
出处 《中外医学研究》 2012年第7期32-33,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献6

二级参考文献37

  • 1王军芳.患者用药的依从性[J].实用医技杂志,2008,15(13). 被引量:9
  • 2周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 3林晓耘,李辉,程心培.华法令抗凝治疗的影响因素和监测[J].中国心脏起搏与心电生理杂志,2005,19(5):410-412. 被引量:9
  • 4韩雅玲,王祖禄.心房颤动患者血栓栓塞并发症的防治[J].中国实用内科杂志,2006,26(2):177-179. 被引量:34
  • 5陈理纳 陈修 等.抗血栓药.心血管药理学(第2版)[M].北京:人民卫生出版社,1997.551-569.
  • 6Segel RG, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Inern Med, 2000,15(1):56-57.
  • 7Gum PA, Kottke-Marchan K, Weish PA,et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Am J Cardiol, 2003, 41 (2): 961-501.
  • 8Grotemeyer KH. Effects of acetylsalicylic acid in stroke: ecidence of nonresponder in a subpopulaiton of treated patients. Thromb Res, 1991 ,63 :587-931.
  • 9Gum PA, Kottke-Marehan K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol,2001 ,88(3):230-500.
  • 10Grotemeyer KH. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res, 1993 ; 71 (5) :397-403.

共引文献27

同被引文献78

  • 1刘松年,荆凌华,李兰英.华法林预防老年非瓣膜病慢性心房颤动患者缺血性脑卒中的临床研究[J].国外医学(内科学分册),2006,33(5):229-230. 被引量:13
  • 2孙学春,盛勇.华法林用于老年非瓣膜病心房纤颤患者的临床观察[J].心血管康复医学杂志,2006,15(5):486-487. 被引量:9
  • 3张刚,曹雪滨,王士雯,崔英凯,毛继康,黄雄,杨梅.非瓣膜病性老年房颤患者华法林抗凝疗效及安全性研究[J].第三军医大学学报,2007,29(19):1918-1919. 被引量:11
  • 4马云青,郑泽琪.不同抗凝强度的华法林对非瓣膜病性房颤抗栓的疗效和安全性[J].江西医学院学报,2007,47(5):59-61. 被引量:8
  • 5Taylor FC, Cohen H, Ebrabim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non- rheumatic atrial fibrillation[J]. BMJ,2001, 322: 321-326.
  • 6Aguilar MI, Hart R, Pearce LA, et al. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non- valvular atrial fibrillation and no history of stroke or transient ischemic attacks [J]. Cochrane Database Syst Rev, 2007VN3: CD006186.
  • 7Jonathan Mant, FD Richard Hobbs, Kate Fletcher, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillatio n Treatment of the Aged Study, BAFTA): a randomised controlled trial[J]. Lancet, 2007, 370: 493-503.
  • 8Amar Rash, Tom Dowries, Robin Portner, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)[J]. Age and Ageing, 2007, 36: 151-156.
  • 9Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thmmboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study[J]. Lancet, 1994, 343: 687-691.
  • 10Chen Xinjun, Wan Ronghua, Jiang Wenlong, et al. Evidence- based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation [J]. Experimental and Therapeutic Medicine, 2013, 6: 413-418.

引证文献9

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部